vs
Embecta Corp.（EMBC）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
Embecta Corp.的季度营收约是BRC Group Holdings, Inc.的1.4倍（$261.2M vs $188.3M），BRC Group Holdings, Inc.净利率更高（47.9% vs 16.9%，领先31.1%），Embecta Corp.同比增速更快（-0.3% vs -21.9%），过去两年Embecta Corp.的营收复合增速更高（-4.6% vs -15.4%）
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
EMBC vs RILY — 直观对比
营收规模更大
EMBC
是对方的1.4倍
$188.3M
营收增速更快
EMBC
高出21.6%
-21.9%
净利率更高
RILY
高出31.1%
16.9%
两年增速更快
EMBC
近两年复合增速
-15.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $261.2M | $188.3M |
| 净利润 | $44.1M | $90.3M |
| 毛利率 | 61.9% | 79.5% |
| 营业利润率 | 31.9% | 32.3% |
| 净利率 | 16.9% | 47.9% |
| 营收同比 | -0.3% | -21.9% |
| 净利润同比 | — | 1710.8% |
| 每股收益（稀释后） | $0.74 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMBCRILY
| Q4 25 | $261.2M | $188.3M | ||
| Q3 25 | $264.0M | $215.3M | ||
| Q2 25 | $295.5M | $188.2M | ||
| Q1 25 | $259.0M | $197.2M | ||
| Q4 24 | $261.9M | $241.0M | ||
| Q3 24 | $286.1M | $225.5M | ||
| Q2 24 | $272.5M | $256.0M | ||
| Q1 24 | $287.2M | $263.4M |
净利润EMBCRILY
| Q4 25 | $44.1M | $90.3M | ||
| Q3 25 | $26.4M | $91.1M | ||
| Q2 25 | $45.5M | $139.5M | ||
| Q1 25 | $23.5M | $-10.0M | ||
| Q4 24 | $0 | $-5.6M | ||
| Q3 24 | $14.6M | $-284.4M | ||
| Q2 24 | $14.7M | $-433.6M | ||
| Q1 24 | $28.9M | $-49.2M |
毛利率EMBCRILY
| Q4 25 | 61.9% | 79.5% | ||
| Q3 25 | 60.0% | 83.7% | ||
| Q2 25 | 66.7% | 81.3% | ||
| Q1 25 | 63.4% | 81.4% | ||
| Q4 24 | 60.0% | 79.8% | ||
| Q3 24 | 60.7% | 82.1% | ||
| Q2 24 | 69.8% | 84.5% | ||
| Q1 24 | 64.6% | 85.3% |
营业利润率EMBCRILY
| Q4 25 | 31.9% | 32.3% | ||
| Q3 25 | 21.4% | 30.4% | ||
| Q2 25 | 31.8% | 5.7% | ||
| Q1 25 | 24.3% | -31.2% | ||
| Q4 24 | 11.0% | -69.2% | ||
| Q3 24 | 9.2% | -36.4% | ||
| Q2 24 | 20.5% | -90.8% | ||
| Q1 24 | 13.6% | -6.1% |
净利率EMBCRILY
| Q4 25 | 16.9% | 47.9% | ||
| Q3 25 | 10.0% | 42.3% | ||
| Q2 25 | 15.4% | 74.1% | ||
| Q1 25 | 9.1% | -5.1% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | 5.1% | -126.1% | ||
| Q2 24 | 5.4% | -169.4% | ||
| Q1 24 | 10.1% | -18.7% |
每股收益（稀释后）EMBCRILY
| Q4 25 | $0.74 | $2.78 | ||
| Q3 25 | $0.44 | $2.91 | ||
| Q2 25 | $0.78 | $4.50 | ||
| Q1 25 | $0.40 | $-0.39 | ||
| Q4 24 | $0.00 | $-0.01 | ||
| Q3 24 | $0.24 | $-9.39 | ||
| Q2 24 | $0.25 | $-14.35 | ||
| Q1 24 | $0.50 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.3M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $-613.1M | $-171.5M |
| 总资产 | $1.1B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EMBCRILY
| Q4 25 | $201.3M | $226.6M | ||
| Q3 25 | $225.5M | $184.2M | ||
| Q2 25 | $230.6M | $267.4M | ||
| Q1 25 | $209.3M | $138.3M | ||
| Q4 24 | $210.0M | $146.9M | ||
| Q3 24 | $267.5M | $159.2M | ||
| Q2 24 | $275.1M | $236.9M | ||
| Q1 24 | $299.8M | $190.7M |
总债务EMBCRILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | $1.4B | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EMBCRILY
| Q4 25 | $-613.1M | $-171.5M | ||
| Q3 25 | $-650.6M | $-260.5M | ||
| Q2 25 | $-669.6M | $-351.7M | ||
| Q1 25 | $-736.2M | $-496.8M | ||
| Q4 24 | $-768.8M | $-488.2M | ||
| Q3 24 | $-738.3M | $-497.6M | ||
| Q2 24 | $-763.7M | $-218.3M | ||
| Q1 24 | $-769.6M | $228.4M |
总资产EMBCRILY
| Q4 25 | $1.1B | $1.7B | ||
| Q3 25 | $1.1B | $1.7B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.1B | $1.5B | ||
| Q4 24 | $1.1B | $1.8B | ||
| Q3 24 | $1.3B | $2.2B | ||
| Q2 24 | $1.3B | $3.2B | ||
| Q1 24 | $1.2B | $5.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.2M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $16.6M | — |
| 自由现金流率自由现金流/营收 | 6.4% | — |
| 资本支出强度资本支出/营收 | 0.2% | — |
| 现金转化率经营现金流/净利润 | 0.39× | 0.29× |
| 过去12个月自由现金流最近4个季度 | $205.8M | — |
8季度趋势，按日历期对齐
经营现金流EMBCRILY
| Q4 25 | $17.2M | $26.2M | ||
| Q3 25 | $84.0M | $-60.6M | ||
| Q2 25 | $81.2M | $-25.6M | ||
| Q1 25 | $31.8M | $184.0K | ||
| Q4 24 | $-5.3M | $-2.7M | ||
| Q3 24 | $26.6M | $19.5M | ||
| Q2 24 | $-2.1M | $111.5M | ||
| Q1 24 | $24.3M | $135.4M |
自由现金流EMBCRILY
| Q4 25 | $16.6M | — | ||
| Q3 25 | $76.7M | — | ||
| Q2 25 | $80.8M | — | ||
| Q1 25 | $31.7M | — | ||
| Q4 24 | $-6.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-11.8M | — | ||
| Q1 24 | $20.9M | — |
自由现金流率EMBCRILY
| Q4 25 | 6.4% | — | ||
| Q3 25 | 29.1% | — | ||
| Q2 25 | 27.3% | — | ||
| Q1 25 | 12.2% | — | ||
| Q4 24 | -2.6% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.3% | — | ||
| Q1 24 | 7.3% | — |
资本支出强度EMBCRILY
| Q4 25 | 0.2% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 3.6% | — | ||
| Q1 24 | 1.2% | — |
现金转化率EMBCRILY
| Q4 25 | 0.39× | 0.29× | ||
| Q3 25 | 3.18× | -0.66× | ||
| Q2 25 | 1.78× | -0.18× | ||
| Q1 25 | 1.35× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.82× | — | ||
| Q2 24 | -0.14× | — | ||
| Q1 24 | 0.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
